BioAegis Therapeutics

BioAegis Therapeutics

  • Founded: 2011
  • Location: North Brunswick, NJ
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: Severe pneumonia
  • Drug types: INF, LNG, PN, NEU, X_X, DRM, RHU, IMM
  • Lead product: Plasma Gelsolin
  • Product link:
  • Funding: $8M Apr 2015

job board

Short description:

Protein replacement therapies

Drug notes:

Also Clin2 sepsis, Clin2 ARDS, Clin1 idiopathic bronchiectasis, Clin1 neuroinflammation, Clin1 trauma/burns, 4 efforts Clin0 inflammatory arthritis, inflammation, lupus, autoimmune disease

Long description:

BioAegis Therapeutics is developing novel protein replacement therapies for infectious, inflammatory and degenerative diseases. Chronic inflammation underpins many diseases and results in the depletion of a naturally occurring plasma protein, gelsolin. Restoring the body with recombinant plasma gelsolin has the potential to prevent lethal ravages of inflammation without perturbing the body’s infection and repair response. The efficacy of recombinant gelsolin has been validated in over twenty models in independent labs including for infections like Influenza and inflammatory diseases like type 2 diabetes. BioAegis is now testing recombinant human gelsolin in clinical trials starting with pneumonia which can be caused by many different types of bacteria and viruses.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy